Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
EMG1 N1-specific pseudouridine methyltransferase (EMG1, also known as Nep1) is an essential nucleolar protein that catalyzes the N1-methylation of pseudouridine (Ψ) at a specific position in 18S ribosomal RNA (typically Ψ1248/Ψ1191 depending on species)[2][3][4]. This modification is required for the synthesis of the hypermodified nucleotide m1acp3Ψ in eukaryotic 18S rRNA, which is critical for the proper assembly and function of the small ribosomal subunit. EMG1 functions both as a methyltransferase and as an assembly factor for ribosome biogenesis, facilitating incorporation of essential ribosomal proteins into the developing subunit. Mutations in EMG1, notably Asp86Gly, lead to Bowen-Conradi syndrome, a fatal ribosomopathy, by destabilizing the protein and impairing ribosome production, which drastically reduces cell growth and division[1][4].
Not applicable. No drugs or chemical inhibitors reported that target EMG1.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on EMG1 N1-specific pseudouridine methyltransferase (EMG1 (also known as Nep1)).